Cefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis : a case report
© 2022 The Authors..
In cystic fibrosis (CF) patients, Gram-negative Burkholderia cepacia complex (Bcc) infections are associated with recurrent pulmonary exacerbations. Bcc organisms are innately resistant to many antibiotics, and infection with B. cenocepacia is a contraindication to lung transplantation. We report a CF patient with severe lung disease, colonized with Bcc, with a history of around nine exacerbations per year for over 10 years, for whom antibiotic regimens (including targeted and broad-spectrum antibiotics) had not cleared infection or extended the interval between exacerbations. After receiving a 2 week cefiderocol-containing regimen, the patient remained stable for more than 5 months without the need for additional antibiotics or hospital admissions for respiratory exacerbations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Access microbiology - 4(2022), 10 vom: 17., Seite acmi000413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nye, Clemency [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burkholderia cenocepacia |
|---|
| Anmerkungen: |
Date Revised 24.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1099/acmi.0.000413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349288437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349288437 | ||
| 003 | DE-627 | ||
| 005 | 20231226042251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1099/acmi.0.000413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349288437 | ||
| 035 | |a (NLM)36415733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nye, Clemency |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis |b a case report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a In cystic fibrosis (CF) patients, Gram-negative Burkholderia cepacia complex (Bcc) infections are associated with recurrent pulmonary exacerbations. Bcc organisms are innately resistant to many antibiotics, and infection with B. cenocepacia is a contraindication to lung transplantation. We report a CF patient with severe lung disease, colonized with Bcc, with a history of around nine exacerbations per year for over 10 years, for whom antibiotic regimens (including targeted and broad-spectrum antibiotics) had not cleared infection or extended the interval between exacerbations. After receiving a 2 week cefiderocol-containing regimen, the patient remained stable for more than 5 months without the need for additional antibiotics or hospital admissions for respiratory exacerbations | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Burkholderia cenocepacia | |
| 650 | 4 | |a cefiderocol | |
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a multi-drug resistance | |
| 700 | 1 | |a Duckers, Jamie |e verfasserin |4 aut | |
| 700 | 1 | |a Dhillon, Rishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Access microbiology |d 2019 |g 4(2022), 10 vom: 17., Seite acmi000413 |w (DE-627)NLM314376968 |x 2516-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g number:10 |g day:17 |g pages:acmi000413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1099/acmi.0.000413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |e 10 |b 17 |h acmi000413 | ||